|
| Publications [#134190] of Mark W. Dewhirst
Papers Published
- RL Page, DW Macy, GK Ogilvie, GL Rosner, MW Dewhirst, DE Thrall, SJ Withrow, MC McEntee, JM Cline, GL Heidner, Phase III evaluation of doxorubicin and whole-body hyperthermia in dogs with lymphoma.,
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, ENGLAND, vol. 8 no. 2
,
pp. 187-97, ISSN 0265-6736
(last updated on 2004/03/30)
Abstract:
Sixty-one dogs with histologically confirmed, untreated, high-grade lymphoma were evaluated and treated with doxorubicin (DOX, 30 mg/m2) alone. Forty-seven dogs (77%) achieved a complete response. Forty-six of the 47 dogs were randomized to receive five additional treatments with doxorubicin +/- whole-body hyperthermia (WBH). Median disease-free survival for the group treated with DOX alone (n = 22) was 189 days and for the DOX plus WBH (n = 24) was 239 days (p = 0.17). After the analysis was adjusted for stratification variables (i.e. institution, weight, stage), the effect of heat on disease-free survival remained statistically insignificant (p = 0.10), but suggested a tendency towards increased disease-free survival in hyperthermic dogs. Intact male dogs had significantly shorter disease-free survival than neutered males and neutered females (178 days vs 266 days, respectively; p = 0.013). No intact females were treated. Body weight, when evaluated as a continuous variable, was found to be a negative prognostic factor (p = 0.036). Tumour volume, stage and institution were not significant. Clinical incidence of cardiac dysfunction was not increased in dogs receiving DOX and WBH; however, post-mortem histological analysis of cardiac tissue suggested that the combined therapy of DOX and WBH was associated with greater myocyte degeneration (p = 0.012) and a tendency for increased cardiac fibrosis (p = 0.08). We concluded that continued refinement of DOX-WBH protocols is warranted, and may ultimately result in significant therapeutic improvement.
Keywords:
Animals • Combined Modality Therapy • Dog Diseases • Dogs • Doxorubicin • Female • Heart • Hyperthermia, Induced • Lymphoma, High-Grade • Male • Myocardium • adverse effects • drug effects • drug therapy • pathology • therapeutic use* • therapy • therapy* • veterinary*
|
